113 related articles for article (PubMed ID: 17973282)
1. In vitro effects of Plasmodium falciparum dihydrofolate reductase inhibitors on normal and cancer cell proliferation.
Rossi T; Coppi A; Bruni E; Sgobba M; Degliesposti G; Rastelli G
ChemMedChem; 2008 Mar; 3(3):421-4. PubMed ID: 17973282
[No Abstract] [Full Text] [Related]
2. Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4(3H)-quinazolinone analogs.
Al-Rashood ST; Aboldahab IA; Nagi MN; Abouzeid LA; Abdel-Aziz AA; Abdel-Hamide SG; Youssef KM; Al-Obaid AM; El-Subbagh HI
Bioorg Med Chem; 2006 Dec; 14(24):8608-21. PubMed ID: 16971132
[TBL] [Abstract][Full Text] [Related]
3. Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells.
Fortunati N; Bertino S; Costantino L; Bosco O; Vercellinatto I; Catalano MG; Boccuzzi G
Cancer Lett; 2008 Feb; 259(2):156-64. PubMed ID: 18006146
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of guanylthiourea derivatives as potential inhibitors of Plasmodium falciparum dihydrofolate reductase enzyme.
Adane L; Bhagat S; Arfeen M; Bhatia S; Sirawaraporn R; Sirawaraporn W; Chakraborti AK; Bharatam PV
Bioorg Med Chem Lett; 2014 Jan; 24(2):613-7. PubMed ID: 24361001
[TBL] [Abstract][Full Text] [Related]
5. In silico screening against wild-type and mutant Plasmodium falciparum dihydrofolate reductase.
Fogel GB; Cheung M; Pittman E; Hecht D
J Mol Graph Model; 2008 Apr; 26(7):1145-52. PubMed ID: 18037315
[TBL] [Abstract][Full Text] [Related]
6. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
Hoeflich KP; O'Brien C; Boyd Z; Cavet G; Guerrero S; Jung K; Januario T; Savage H; Punnoose E; Truong T; Zhou W; Berry L; Murray L; Amler L; Belvin M; Friedman LS; Lackner MR
Clin Cancer Res; 2009 Jul; 15(14):4649-64. PubMed ID: 19567590
[TBL] [Abstract][Full Text] [Related]
7. Tyrphostin AG1478 suppresses proliferation and invasion of human breast cancer cells.
Zhang YG; Du Q; Fang WG; Jin ML; Tian XX
Int J Oncol; 2008 Sep; 33(3):595-602. PubMed ID: 18695891
[TBL] [Abstract][Full Text] [Related]
8. In-vitro antiproliferative activities and kinase inhibitory potencies of meridianin derivatives.
Rossignol E; Debiton E; Fabbro D; Moreau P; Prudhomme M; Anizon F
Anticancer Drugs; 2008 Sep; 19(8):789-92. PubMed ID: 18690090
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors: from bench to clinic.
Paris M; Porcelloni M; Binaschi M; Fattori D
J Med Chem; 2008 Mar; 51(6):1505-29. PubMed ID: 18247554
[No Abstract] [Full Text] [Related]
10. Design, synthesis, and biological activity of a family of novel ceramide analogues in chemoresistant breast cancer cells.
Antoon JW; Liu J; Gestaut MM; Burow ME; Beckman BS; Foroozesh M
J Med Chem; 2009 Sep; 52(18):5748-52. PubMed ID: 19694470
[TBL] [Abstract][Full Text] [Related]
11. CDDO-Me inhibits proliferation, induces apoptosis, down-regulates Akt, mTOR, NF-kappaB and NF-kappaB-regulated antiapoptotic and proangiogenic proteins in TRAMP prostate cancer cells.
Deeb D; Gao X; Dulchavsky SA; Gautam SC
J Exp Ther Oncol; 2008; 7(1):31-9. PubMed ID: 18472640
[TBL] [Abstract][Full Text] [Related]
12. [Effect of EGFR (epidermal growth factor receptor) inhibitors on apoptosis and cell proliferation in pancreatic cancer].
Agaev B; Muslimov G; Iagublu V; Geĭdrikh B
Eksp Klin Gastroenterol; 2008; (2):84-90. PubMed ID: 19145871
[No Abstract] [Full Text] [Related]
13. Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification.
You QD; Li ZY; Huang CH; Yang Q; Wang XJ; Guo QL; Chen XG; He XG; Li TK; Chern JW
J Med Chem; 2009 Sep; 52(18):5649-61. PubMed ID: 19715319
[TBL] [Abstract][Full Text] [Related]
14. Tumor cell metabolism: cancer's Achilles' heel.
Kroemer G; Pouyssegur J
Cancer Cell; 2008 Jun; 13(6):472-82. PubMed ID: 18538731
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative activity against MCF-7 breast cancer cells by diamino-triazaspirodiene antifolates.
Ma X; Woon RS; Ho PC; Chui WK
Chem Biol Drug Des; 2009 Sep; 74(3):322-6. PubMed ID: 19703036
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of N-(5,7-diamino-3-phenyl-quinoxalin-2-yl)-3,4,5-substituted anilines and N-[4[(5,7-diamino-3-phenylquinoxalin-2-yl)amino]benzoyl]-l-glutamic acid diethyl ester: evaluation of in vitro anti-cancer and anti-folate activities.
Corona P; Loriga M; Costi MP; Ferrari S; Paglietti G
Eur J Med Chem; 2008 Jan; 43(1):189-203. PubMed ID: 17532099
[TBL] [Abstract][Full Text] [Related]
17. Enzastaurin and pemetrexed exert synergistic antitumor activity in thyroid cancer cell lines in vitro.
Oberschmidt O; Eismann U; Schulz L; Struck S; Blatter J; Lahn MM; Ma D; Hanauske AR
Int J Clin Pharmacol Ther; 2005 Dec; 43(12):603-4. PubMed ID: 16372535
[No Abstract] [Full Text] [Related]
18. Rational modification of the lead molecule: Enhancement in the anticancer and dihydrofolate reductase inhibitory activity.
Kaur J; Kaur S; Singh P
Bioorg Med Chem Lett; 2016 Apr; 26(8):1936-40. PubMed ID: 26979156
[TBL] [Abstract][Full Text] [Related]
19. Thymidylate synthase inhibitors.
Ackland SP; Clarke SJ; Beale P; Peters GJ
Cancer Chemother Biol Response Modif; 2002; 20():1-36. PubMed ID: 12703198
[No Abstract] [Full Text] [Related]
20. Apoptosis as the predominant tumor cell response to chemotherapy and irradiation: a case of TUNEL vision?
Gewirtz DA; Elmore LW
Curr Opin Investig Drugs; 2005 Dec; 6(12):1199. PubMed ID: 16370385
[No Abstract] [Full Text] [Related]
[Next] [New Search]
